ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 6, 2014, Pages 2777-2783

  Wan, Wei Na ^a   Zhang, Yi Xia ^a   Wang, Xue Mei ^a   Liu, Yan Jun ^a   Zhang, Yu Qin ^a   Que, Yan Hong ^a   Zhao, Wen Jing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

5 year survival rate; ATAD2; CA 125; Ovarian cancer; Prognosis

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ATAD2 PROTEIN, HUMAN; DNA BINDING PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA;

ANTAGONISTS AND INHIBITORS; CANCER STAGING; COLLOID CARCINOMA; CYSTADENOCARCINOMA; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENETICS; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; OMENTUM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SURVIVAL RATE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA, MUCINOUS; ADENOSINE TRIPHOSPHATASES; BLOTTING, WESTERN; CYSTADENOCARCINOMA, SEROUS; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; OMENTUM; OVARIAN NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84899836020     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.6.2777     Document Type: Article

References (36)

1. Bodoor K, Haddad Y, Alkhateeb A, et al (2014). DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients. Asian Pac J Cancer Prev, 15, 75-84
2. Caron C, Lestrat C, Marsal S, et al (2010). Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene, 29, 5171-81.
3. Chan KK, Wei N, Liu SS, et al (2008). Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol, 111, 144-51.
4. Ciró M, Prosperini E, Quarto M, et al (2009). ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res, 69, 8491-8.
5. Coser KR, Chesnes J, Hur J, et al (2003). Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc Natl Acad Sci USA, 100, 13994-9.
6. Desmedt C, Piette F, Loi S, et al (2007). Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res, 13, 3207-14.
7. Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M (2006). A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev, 20, 2513-26.
8. Foekens JA, Atkins D, Zhang Y, et al (2006). Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol, 24, 1665-71.
9. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR (2004). Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother, 58, 24-38.
10. Ghisletti S, Meda C, Maggi A, Vegeto E (2005). 17β-estradiol inhibits inflammatory gene expression by controlling NF-κB intracellular localization. Mol Cell Biol, 25, 2957-68.
11. Haibe-Kains B, Desmedt C, Piette F, et al (2008). Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics, 9, 394.
12. Horn LC, Beckmann MW, Beller A, et al (2010). Changes in the TNM classification of gynecological tumors. Pathologe, 31, 367-73.
13. Hsia EY, Kalashnikova EV, Revenko AS, et al (2010). Deregulated E2F and the AAA+ coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer. Mol Cancer Res, 8, 183-93.
14. Hsia EY, Zou JX, Chen HW (2009). The roles and action mechanisms of p160/SRC coactivators and the ANCCA coregulator in cancer. Prog Mol Biol Transl Sci, 87, 261-98.
15. Ivshina AV, George J, Senko O, et al (2006). Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res, 66, 10292-301.
16. Jemal A, Murray T, Ward E, et al (2005). Cancer statistics. CA Cancer J Clin, 55, 10-30.
17. Kalashnikova EV, Revenko AS, Gemo AT, et al (2010). ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res, 70, 9402-12.
18. Kobayashi E, Ueda Y, Matsuzaki S, et al (2012). Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev, 21, 1902-12.
19. Li J, Dowdy S, Tipton T, et al (2009). HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn, 9, 555-66.
20. Lutz AM, Willmann JK, Drescher CW, et al (2011). Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology, 259, 329-45.
21. Ma XJ, Salunga R, Tuggle JT, et al (2003). Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A, 100, 5974-9.
22. Ngwenya S, Safe S (2003). Cell context-dependent differences in the induction of E2F-1 gene expression by 17 beta-estradiol in MCF-7 and ZR-75 cells. Endocrinology, 144, 1675-85.
23. Nossov V, Amneus M, Su F, et al (2008). The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol, 199, 215-23.
24. O'Lone R, Frith MC, Karlsson EK, Hansen U (2004). Genomic targets of nuclear estrogen receptors. Mol Endocrinol, 18, 1859-75.
25. Prajoko YW, Aryandono T (2014). Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer. Asian Pac J Cancer Prev, 15, 595-98
26. Raeder MB, Birkeland E, Trovik J, et al (2013). Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One, 8, e54873.
27. Rao BR, Slotman BJ (1991). Endocrine factors in common epithelial ovarian cancer. Endocr Rev, 12, 14-26.
28. Revenko AS, Kalashnikova EV, Gemo AT, Zou JX, Chen HW (2010). Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol, 30, 5260-72.
29. Sorensen SS, Mosgaard BJ (2011). Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull, 58, A4331.
30. Teschendorff AE, Naderi A, Barbosa-Morais NL, et al (2006). A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol, 7, R101.
31. van 't Veer LJ, Dai H, van de Vijver MJ, et al (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-6.
32. Visintin I, Feng Z, Longton G, et al (2008). Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res, 14, 1065-72.
33. Wang Y, Klijn JG, Zhang Y, et al (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, 365, 671-9.
34. Wrzeszczynski KO, Varadan V, Byrnes J, et al (2011). Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS One, 6, e28503.
35. Zou JX, Guo L, Revenko AS, et al (2009). Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res, 69, 3339-46.
36. Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW (2007). ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci USA, 104, 18067-72.